Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Share-based Compensation (2016 - 2025)

OptimizeRx's Share-based Compensation history spans 14 years, with the latest figure at $2.0 million for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 24.88% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $7.9 million, down 63.42%, while the annual FY2024 figure was $11.5 million, 16.4% down from the prior year.
  • Share-based Compensation for Q3 2025 was $2.0 million at OptimizeRx, up from $1.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $13.2 million in Q4 2023 and bottomed at -$7.3 million in Q3 2023.
  • The 5-year median for Share-based Compensation is $2.9 million (2024), against an average of $2.7 million.
  • The largest annual shift saw Share-based Compensation surged 538.78% in 2022 before it tumbled 271.68% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $3.1 million in 2021, then surged by 36.4% to $4.3 million in 2022, then soared by 208.63% to $13.2 million in 2023, then crashed by 77.71% to $2.9 million in 2024, then tumbled by 33.4% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Share-based Compensation are $2.0 million (Q3 2025), $1.5 million (Q2 2025), and $1.6 million (Q1 2025).